Ngapas, Rahma M.
HRN: 10-43-87 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/16/2022
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
05/16/2022
05/22/2022
IV
1.5G
Q6
Wound Infection
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes